AVH.AX - AVITA Therapeutics, Inc.
| Previous close | 8.52 |
| Open | 8.39 |
| Bid | 8.46 x 0 |
| Ask | 7.88 x 0 |
| Day's range | 7.73 - 8.48 |
| 52-week range | 0.32 - 9.58 |
| Volume | 887,553 |
| Avg. volume | 9,888,137 |
| Market cap | 168.114M |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.00 |
| Earnings date | 30 Apr 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.21 |
- Business Wire
AVITA Therapeutics Provides Company Update and Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2020
AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today preliminary unaudited results for the fourth quarter and full year ended June 30, 2020, together with a company update.
- Simply Wall St.
What Type Of Shareholders Own The Most Number of AVITA Therapeutics, Inc. (ASX:AVH) Shares?
A look at the shareholders of AVITA Therapeutics, Inc. (ASX:AVH) can tell us which group is most powerful...
- Business Wire
AVITA Medical Limited Implementation of the Scheme of Arrangement to Redomicile from Australia to the United States of America
AVITA Medical Limited ACN 058 466 523 (Company) is pleased to announce that the scheme of arrangement to effect the redomiciliation of the Company and its subsidiaries (Avita Group) from Australia to the United States of America (Scheme) has today been implemented. As previously announced, the Scheme was approved by the Company’s shareholders at the Scheme meeting held via live webcast on 15 June 2020 and approved by the Federal Court of Australia on 22 June 2020.
- Business Wire
AVITA Medical Limited Proposed Redomiciliation to the United States of America - Court Approves Scheme of Arrangement
AVITA Medical Limited ACN 058 466 523 (Company) is pleased to announce that the Federal Court of Australia (Court) has today approved the scheme of arrangement to effect a redomiciliation of the Company and its subsidiaries (Avita Group) from Australia to the United States of America (Scheme), under which AVITA Therapeutics, Inc. ARBN 641 288 155 (Avita US), a company incorporated in the State of Delaware in the United States of America, will become the parent company of the Avita Group.
- Business Wire
AVITA Medical Limited Proposed Redomiciliation to the United States of America - Results of Scheme Meeting
AVITA Medical Limited Proposed redomiciliation to the United States of America - Results of Scheme Meeting
- Business Wire
AVITA Medical Limited Proposed Redomiciliation to the United States of America - Chair’s Address to Scheme Meeting
In accordance with ASX Listing Rule 3.13.3, AVITA Medical Limited ACN 058 466 523 (Company) is pleased to provide a copy of the Chair’s address for the Scheme Meeting being held virtually at 9.00am (AEST) today, being Monday, 15 June 2020.
- Business Wire
AVITA Medical Limited Proposed Redomiciliation to the United States of America - Scheme Meeting on Monday, 15 June 2020 at 9.00am (AEST)
AVITA Medical Limited ACN 058 466 523 (Company) is pleased to confirm that the general meeting to consider a resolution to approve the proposed scheme of arrangement to effect a redomiciliation of the Company and its subsidiaries from Australia to the United States of America (Scheme Meeting) is being held by way of live webcast at 9.00am (AEST) on Monday, 15 June 2020 (being 7.00pm (EDT) on Sunday, 14 June 2020).
- Business Wire
AVITA Medical Limited Proposed Redomiciliation to the United States of America – Satisfaction of FIRB Condition
AVITA Medical Limited Proposed redomiciliation to the United States of America – Satisfaction of FIRB Condition
- Business Wire
AVITA Medical Files RECELL® System Investigational Device Exemption (IDE) Application with the U.S. Food and Drug Administration for Treatment of Vitiligo
AVITA Medical Limited (ASX: AVH) (NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, today announced that it has submitted an Investigational Device Exemption (IDE) supplement with the U.S. Food and Drug Administration (FDA) for the initiation of a pivotal clinical trial to investigate the RECELL® System for the treatment of vitiligo.
- Business Wire
AVITA Medical to Participate at the Jefferies Virtual Healthcare Conference
AVITA Medical to Participate at the Jefferies Virtual Healthcare Conference
- Business Wire
AVITA Medical to Participate at Oppenheimer's MedTech Summit
AVITA Medical to Participate at Oppenheimer's MedTech Summit
- Business Wire
AVITA Medical Limited Proposed Redomiciliation to the United States of America – Registration of Scheme Booklet with ASIC and Financial Reporting Relief Granted by ASIC
AVITA Medical Limited (Company) (ASX:AVH) (NASDAQ:RCEL) is pleased to announce that the Australian Securities and Investments Commission (ASIC) has registered the scheme booklet (Scheme Booklet) in relation to the proposed scheme of arrangement under which AVITA Therapeutics, Inc. (Avita US), a newly-formed company incorporated in Delaware in the United States of America, will become the parent company of the Company and its subsidiaries (Avita Group) for the purposes of effecting a redomiciliation of the Avita Group from Australia to the United States of America (Scheme).
- Business Wire
AVITA Medical Limited Proposed redomiciliation to the United States of America – Federal Court of Australia orders convening of Scheme Meeting
AVITA Medical Limited Proposed redomiciliation to the United States of America – Federal Court of Australia orders convening of Scheme Meeting
- Simply Wall St.
Companies Like Avita Medical (ASX:AVH) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Motley Fool
2 Stocks That Offer Explosive Potential Gains
Identifying tomorrow's stock market winners requires unwavering curiosity. Using its innovations in skin regeneration technology, Australia-based Avita Medical (NASDAQ: RCEL) has created an alternative to skin grafts that involves less time, pain, and risk of infection. Avita's medical device, called the RECELL system, prepares a spray-on suspension using a small amount of a patient's own skin.
- Business Wire
AVITA Medical Reports Third Quarter Fiscal 2020 Financial Results and Company Update
AVITA Medical Reports Third Quarter Fiscal 2020 Financial Results and Company Update
- Business Wire
AVITA Medical Announces Intention to Redomicile to the United States of America
AVITA Medical Announces Intention to Redomicile to the United States of America
- Business Wire
AVITA Medical Provides Preliminary Top Line Results for the Third Quarter and COVID-19 Update
AVITA Medical Provides Preliminary Top Line Results for the Third Quarter and COVID-19 Update
- Business Wire
RECELL® System Data Accepted to 52nd Annual American Burn Association Meeting Available Online
RECELL® System Data Accepted to 52nd Annual American Burn Association Meeting Available Online
- Simply Wall St.
How Many Avita Medical Limited (ASX:AVH) Shares Did Insiders Buy, In The Last Year?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
- Business Wire
First Patient Enrolled in AVITA Medical’s Pivotal Study Evaluating RECELL® System for Pediatric Scald Injuries
AVITA Medical Limited (ASX: AVH) (NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today the initiation of a pivotal trial for the treatment of pediatric scald injuries with enrollment of the first patient at the Arizona Burn Center at Valleywise Medical Health Center in Phoenix, AZ. This study seeks to demonstrate that treatment with the RECELL System of partial-thickness burn injuries within 72-hours can safely and effectively increase the incidence of healing at day 10 when compared to a standard wound dressing.
- Business Wire
AVITA Medical to Attend the 2020 BTIG Healthcare Conference
AVITA Medical to Attend the 2020 BTIG Healthcare Conference
- Business Wire
First Patient Enrolled in AVITA Medical’s Pivotal Study Evaluating RECELL System for Soft Tissue Reconstruction
AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, announced today the initiation of the pivotal study for soft tissue reconstruction with the enrollment of the first patient at the Arizona Burn Center at Valleywise Medical Health Center in Phoenix, AZ. This study will evaluate the safety and effectiveness of the RECELL® System when used as an adjunct to meshed autografts in patients undergoing reconstruction of skin defects not associated with a burn injury.
- Simply Wall St.
Did The Underlying Business Drive Avita Medical's (ASX:AVH) Lovely 730% Share Price Gain?
We think all investors should try to buy and hold high quality multi-year winners. And we've seen some truly amazing...
